EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Ping An Biomedical Co., Ltd. (PASW) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Ping An Biomedical Co., Ltd. $0.05, price $0.12, upside -59.9%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Consumer Cyclical · US · ISIN KYG5880S1131

PA Ping An Biomedical Co., Ltd. logo Thin data Sep 27, 2026

Ping An Biomedical Co., Ltd.

PASW · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0500 · Strongly overvalued (−59.9%)
!Quality 35/100
!Weak Growth (revenue 3y −33.2 %/yr)
!Loss-making · -37.6% net margin (TTM)
!negative free cash flow
!Trails peers (0/7)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Ping An Biomedical Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3.30 $0.1160 Fair Value $0.0500 Jul 2025 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

14‑month range $0.1160 – $3.30 · fair‑value band $0.0300 – $0.0600 · the $0.1248 price screens above the $0.0500 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Ping An Biomedical Co. in your weekly email

Every Wednesday you see whether Ping An Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ping An Biomedical Co., Ltd., through its subsidiaries, provides supply chain management services in the apparel industry in China, Hong Kong, Cambodia, and Europe. The company offers market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management.

Show more

Ping An Biomedical Co., Ltd., through its subsidiaries, provides supply chain management services in the apparel industry in China, Hong Kong, Cambodia, and Europe. The company offers market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. It also engages in the manufacturing and trading of yarns, textiles, and finished garments; real estate property investment; and warehousing services. The company serves brand owners, textile manufacturers, apparel sourcing agents, and online fashion and garment retailers. It was formerly known as Majestic Ideal Holdings Ltd. and changed its name to Ping An Biomedical Co., Ltd. in September 2025. The company was founded in 2013 and is based in Cheung Sha Wan, Hong Kong. Ping An Biomedical Co., Ltd. operates as a subsidiary of Action Holdings Limited.

Stock analysis

Ping An Biomedical Co., Ltd. (PASW) currently trades at $0.1248, while our model-based Fair Value estimate is $0.0500, 59.9% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0300 (bear) to $0.0600 (bull), the price of $0.1248 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Consumer Cyclical sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Ping An Biomedical Co., Ltd. reported revenue of 34.1M CNY in FY2025 versus 99.5M CNY in FY2021, a compound −23.5%/yr. Reported net income was −12.8M CNY in FY2025.

Key figures

Market cap $17.3M · P/S ratio 0.65 · EPS (TTM) $−0.1100 · Net margin −37.6% · Return on equity −67.4% · Return on assets (EBIT) 0.7% · Operating margin −69.6% · Revenue (TTM) 34.1M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 89% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Cyclical peers we cover trades at −19% fair-value upside, at −60%, PASW screens richer than that median.

Fair Value models

Bear $0.0300 Fair Value $0.0500 Bull $0.0600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0300 $0.0400 $0.0500 53
All 1 models by family
Asset-Based
NCAV (Graham) $0.0300 $0.0400 $0.0500 53

Open the full fair value analysis →

Notify me when PASW reaches fair value

Put PASW on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 35/100

Of which business quality 37 · Market factors (momentum, volatility) 8

Profitability 7
Margins and returns on capital today
Quality Growth 11
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 49
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−61.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−33.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.3% (2021) → −43.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PASW screens overvalued: fair value 60% below the price. Compare with Tongkun Group →

Compare Ping An Biomedical Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Textile Manufacturing · 334 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −60.3% · Bottom 25%
Profitability
Return on assets −14.7% · Bottom 25%
Net margin (TTM) −37.6% · Bottom 25%
Operating margin (TTM) −69.6% · Bottom 25%
Growth and dividend
Revenue growth −62.0% · Bottom 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Textile Manufacturing stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Tongkun Group 601233 ¥23.26 ¥14.53 −38%
Shenzhou International Group 2313 HK$34.08 HK$71.99 +111%
Inner Mongolia ERDOS Resources Co 600295 ¥12.80 ¥14.35 +12%
K.P.R. Mill Limited KPRMILL ₹1,106 ₹901.34 −19%
Zhejiang Orient Holdings 600120 ¥4.65 ¥2.40 −48%
Welspun Living Limited WELSPUNLIV ₹239.17 ₹47.77 −80%
Ruentex Industries Ltd 2915 58.30 TWD 106.63 TWD +83%
Albany International Corp AIN $59.61 $25.00 −58%
Bros Eastern.,Ltd 601339 ¥7.25 ¥7.87 +9%
Vardhman Textiles Limited VTL ₹534.60 ₹269.96 −50%

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ping An Biomedical Co., Ltd. · Fair Value
$0.0500 −60%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Ping An Biomedical Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/PASW

Frequently asked questions

Is Ping An Biomedical Co., Ltd. (PASW) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0500 versus a price of $0.1248, about −60% upside (overvalued).
What is the fair value of PASW?
Our model-based fair value for Ping An Biomedical Co., Ltd. is $0.0500 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.1248.
What is the quality score of PASW?
Ping An Biomedical Co., Ltd. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ping An Biomedical Co., Ltd. (PASW)?
Our model-based price target is the fair value of $0.0500 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.0300, optimistic scenario $0.0600. It is a calculation from audited fundamentals, not an analyst target.
What is the Ping An Biomedical Co., Ltd. stock forecast for 2026?
Our models put fair value at $0.0500, about −60% upside versus a price of $0.1248 (overvalued). Cautious scenario $0.0300, optimistic scenario $0.0600. The calculation is refreshed regularly with new filings.
What is the revenue of Ping An Biomedical Co., Ltd. (PASW)?
Ping An Biomedical Co., Ltd. reported trailing-twelve-month revenue of about 34.1M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Ping An Biomedical Co., Ltd. (PASW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ping An Biomedical Co., Ltd. it is $0.0500 per share (as of Sep 27, 2026), against a price of $0.1248. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Ping An Biomedical Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, PASW trades above its calculated fair value: price $0.1248, fair value $0.0500, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PASW?
No. The price is what the market pays today ($0.1248); the fair value is what the company's own numbers justify ($0.0500). For Ping An Biomedical Co., Ltd. the two are $0.0748 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ping An Biomedical Co., Ltd. worth?
The market values Ping An Biomedical Co., Ltd. at about $17.3M (market capitalisation, as of Sep 27, 2026). Per share that is $0.1248; our models calculate a fair value of $0.0500 per share.
What do the bullish and bearish scenarios say about PASW?
Our models span a range for Ping An Biomedical Co., Ltd.: cautious scenario $0.0300, base $0.0500, optimistic $0.0600 per share (as of Sep 27, 2026, price $0.1248). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ping An Biomedical Co., Ltd. (PASW)?
Balance-sheet figures for Ping An Biomedical Co., Ltd. (as of Sep 27, 2026): return on equity −67.4%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is PASW from its 52-week high?
Ping An Biomedical Co., Ltd. trades at $0.1248, about 89% below its 52-week high of $1.09 and 8% above the low of $0.1160 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0500 is for.
Which stocks are comparable to Ping An Biomedical Co., Ltd.?
From the same area (Consumer Cyclical) we also value Tongkun Group, Shenzhou International Group, Inner Mongolia ERDOS Resources Co, K.P.R. Mill Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ping An Biomedical Co., Ltd. stock attractive at the current price?
The data as of Sep 27, 2026: price $0.1248, calculated fair value $0.0500 (−60%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PASW calculated?
We run Ping An Biomedical Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ping An Biomedical Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ping An Biomedical Co., Ltd. (PASW)?
The closing price on Oct 2, 2026 was $0.1248. Our model-based fair value is $0.0500, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ping An Biomedical Co., Ltd. right now?
The price sits above even our optimistic bull case ($0.0600). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0300 to $0.0600) leaves room in how you read the outcome.

Key figures of Ping An Biomedical Co., Ltd.

How large is the market capitalisation of Ping An Biomedical Co., Ltd. (PASW)?
The market capitalisation of Ping An Biomedical Co., Ltd. is $17.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ping An Biomedical Co., Ltd. (PASW)?
The price-to-sales ratio of Ping An Biomedical Co., Ltd. is 0.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ping An Biomedical Co., Ltd. (PASW)?
Earnings per share at Ping An Biomedical Co., Ltd. are $−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ping An Biomedical Co., Ltd. (PASW)?
The net margin of Ping An Biomedical Co., Ltd. is −37.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ping An Biomedical Co., Ltd. (PASW)?
The return on equity (ROE) of Ping An Biomedical Co., Ltd. is −67.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ping An Biomedical Co., Ltd. (PASW)?
On an EBIT basis the return on assets of Ping An Biomedical Co., Ltd. is 0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ping An Biomedical Co., Ltd. (PASW)?
The operating margin of Ping An Biomedical Co., Ltd. is −69.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ping An Biomedical Co., Ltd. (PASW)?
Revenue at Ping An Biomedical Co., Ltd. is growing −62.0% versus a year earlier (3y avg −33.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ping An Biomedical Co., Ltd. (PASW) generate?
The free cash flow of Ping An Biomedical Co., Ltd. is −6.4M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ping An Biomedical Co., Ltd. (PASW) carry?
The net debt of Ping An Biomedical Co., Ltd. is 8.8M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ping An Biomedical Co., Ltd. in the live analysis

One click puts Ping An Biomedical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.